N-Acetyl Semax Amidate: Published Research

Introduction

N-Acetyl Semax Amidate (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂) is the dually terminal-modified variant of Semax, a synthetic heptapeptide analog of ACTH(4–10) first developed in Russia during the 1980s. The peer-reviewed literature on this compound class spans several decades, with most mechanistic and in vivo research conducted using Semax or N-acetyl Semax, and with structural pharmacology studies addressing the fully amidated form directly. This article summarizes the primary peer-reviewed studies most relevant to understanding N-Acetyl Semax Amidate, grouped by research methodology and subject matter. All findings described below are attributed to the specific compound and model system used in each cited source, and findings from animal or cell-culture models do not establish safety or efficacy in humans. The mechanistic framework underpinning this body of research is described in the N-Acetyl Semax Amidate mechanism of action article.

Methodology Types

The research corpus covering Semax-family peptides spans several distinct methodological approaches:

In vivo rodent neurochemistry: Administration of peptide to intact rats or mice, followed by measurement of neurotransmitter metabolites, neurotrophin protein or mRNA levels, or behavioral endpoints.

Ex vivo gene expression analysis: Measurement of mRNA transcripts for neurotrophin genes (BDNF, NGF, NT-3) and their receptors (TrkA, TrkB, TrkC) in brain tissue from rodent ischemia models.

Genome-wide transcriptomics and proteomics: RNA sequencing or mass spectrometry-based approaches characterizing global gene or protein expression changes associated with peptide treatment in ischemia models.

Cell culture (in vitro): Dissociated primary neuron cultures used to assess neuron survival, enzyme activity, and calcium dynamics at defined peptide concentrations.

Coordination chemistry (in vitro): Spectroscopic and potentiometric characterization of metal-binding properties of the peptide and its analogs at physiological pH.

Pharmacokinetics: Radiometric tracking of labeled peptide following intranasal administration to characterize brain penetration and metabolite profiles.

Summary of Studies

BDNF Protein Binding and Expression in Rat Basal Forebrain (Dolotov et al., 2006)

Dolotov and colleagues (2006) published a study in the Journal of Neurochemistry characterizing specific Semax binding sites in rat brain membrane preparations. Using tritium-labeled Semax in radioligand binding assays, the investigators identified saturable, reversible binding in basal forebrain membranes with a dissociation constant (KD) of approximately 2.4 nM and a binding maximum (Bmax) of 33.5 fmol/mg protein [1].

Separate in vivo experiments in the same publication reported that intranasal Semax produced a rise in BDNF protein levels selectively in the rat basal forebrain at three hours post-administration, without an analogous effect in the cerebellum. TrkB receptor phosphorylation at the hippocampus was reported to increase approximately 1.6-fold, alongside a 3-fold increase in BDNF exon III mRNA. The authors interpreted these results as consistent with a mechanism involving Semax engagement of basal forebrain receptor sites linked to BDNF signaling [1].

Findings from research models do not establish safety or efficacy in humans. SpartaLabs makes no claims about the use of this compound.

Temporal Dynamics of NGF and BDNF Gene Expression (Shadrina et al., 2010)

A study by Shadrina, Kolomin and colleagues (2010) in the Journal of Molecular Neuroscience examined the time course of BDNF and NGF gene expression in three brain regions and the retina following a single Semax administration to male Wistar rats. Measurements were taken at six time points from 20 minutes to 24 hours using real-time PCR [2].

The investigators reported divergent, region-specific responses: NGF and BDNF mRNA in the hippocampus and retina were decreased at 20 minutes, while frontal cortex levels were elevated at the same time point. Retinal BDNF expression was significantly elevated at 90 minutes. Both neurotrophin genes showed a complex, non-monotonic temporal pattern that differed across the three brain regions examined. The authors described the findings as indicating multidirectional neurotrophin regulation under Semax, an observation that has informed subsequent hypotheses about region-specific receptor engagement in this peptide class [2].

Dopaminergic and Serotonergic Systems in Rodents (Kolomin et al., 2006)

Kolomin and colleagues (2006) measured striatal neurotransmitter and metabolite content in rats following Semax administration using in vivo microdialysis and tissue extraction, publishing the results in Neurochemical Research [3].

The study reported a 25% increase in tissue content of 5-HIAA (the primary serotonin metabolite) in the striatum at two hours, and a progressive increase in extracellular 5-HIAA reaching approximately 180% of baseline within one to four hours. Dopamine and its metabolites were not significantly altered by Semax alone. In a co-administration paradigm, Semax administered 20 minutes prior to d-amphetamine was reported to amplify amphetamine's effect on extracellular dopamine and on locomotor activity. The authors proposed a modulatory interaction between Semax and the serotonergic system, with downstream gating of dopaminergic responsiveness under pharmacological stimulation [3].

Cholinergic Neuron Survival in Basal Forebrain Culture (Grivennikov et al., 2008)

Grivennikov, Dolotov, Zolotarev, Andreeva, Myasoedov and colleagues (2008) reported an in vitro study of Semax effects on dissociated rat basal forebrain neurons, published in Restorative Neurology and Neuroscience [4].

At 100 nM, Semax was reported to be associated with approximately 1.5–1.7-fold greater cholinergic neuron survival relative to untreated controls in culture. Choline acetyltransferase (ChAT) enzymatic activity was significantly elevated. The investigators noted specificity for the cholinergic phenotype: neither GABA-ergic neurons nor total neuron-specific enolase-positive neurons were significantly affected at the tested concentration. The study was conducted in dissociated cell culture and did not assess systemic or in vivo outcomes [4].

Neurotrophin and Receptor Transcription in Ischemia (Dmitrieva et al., 2010)

Dmitrieva, Povarova, Skvortsova, Myasoedov and colleagues (2010) compared the effect of Semax and the C-terminal metabolite Pro-Gly-Pro on neurotrophin gene transcription in rat cortex following permanent middle cerebral artery occlusion, reporting in Cellular and Molecular Neurobiology [5].

Semax was reported to activate BDNF, TrkC, and TrkA gene transcription at three hours post-occlusion; NGF transcription was activated at 24 and 72 hours. The researchers noted that Pro-Gly-Pro showed partially overlapping, partially distinct effects on the same gene set — establishing that the intact Semax sequence and its C-terminal metabolite are pharmacologically non-equivalent in their effects on neurotrophin gene transcription under ischemic conditions. This distinction has informed subsequent understanding of which pharmacological effects arise from the parent peptide versus its degradation products [5].

Genome-Wide Gene Expression in Focal Ischemia (Medvedeva et al., 2014)

Medvedeva and colleagues (2014) conducted genome-wide RNA sequencing in a rat permanent middle cerebral artery occlusion (pMCAO) model with and without Semax treatment, reporting results in BMC Genomics [6].

The analysis identified broad changes in expression of genes associated with immune response and vascular function. At three hours post-occlusion, Semax was associated with altered expression in a set of immune-system genes; at 24 hours, the investigators described a more pronounced effect on immunoglobulin- and chemokine-encoding transcripts. Vascular-system genes, including those associated with endothelial migration, hematopoiesis, and vasculogenesis, showed altered expression at both time points. The transcriptome-scale scope of this study informed subsequent proteomic investigations of the peptide's downstream effects [6].

Brain Proteomics in Ischemia-Reperfusion (Sudarkina et al., 2021)

Sudarkina, Filippenkov and colleagues (2021) applied mass spectrometry-based proteomics in a rat transient ischemia-reperfusion model to characterize protein-level changes associated with Semax treatment, publishing in the International Journal of Molecular Sciences [7].

More than 40 proteins were identified as significantly associated with Semax exposure relative to ischemia-reperfusion without treatment. The investigators described patterns consistent with changes in apoptotic and neuroinflammatory signaling proteins and in antioxidant enzyme and synaptic plasticity-related protein levels. As a proteomics study, findings reflect associations between peptide exposure and protein abundance rather than causal mechanistic assignments [7].

Metal Coordination Chemistry of N-Acetyl Semax (Magrì et al., 2016)

The most directly relevant published study for the N-acetyl modified variant was reported by Magrì and colleagues (2016) in the Journal of Inorganic Biochemistry. The investigators synthesized N-acetyl Semax and characterized its copper(II) and zinc(II) coordination properties, comparing results directly with those from unmodified Semax across physiological pH ranges [8].

At pH 7.4, unmodified Semax formed a CuN4 chromophore incorporating the free alpha-amino group at the N-terminus. N-acetyl Semax, with the alpha-amino group blocked, formed a CuN3O chromophore, reflecting a geometrically distinct copper complex. Zinc(II) binding was not substantially altered by N-terminal acetylation. In SH-SY5Y neuroblastoma cell assays, unmodified Semax was found to confer partial protection against copper-induced cytotoxicity through its copper-chelation geometry, an activity that N-acetyl Semax did not replicate — attributable to the loss of the free terminal amine. This study established that N-terminal acetylation meaningfully alters the copper pharmacology of the Semax peptide family, while zinc interactions and other receptor-mediated activities remain distinct lines of investigation [8].

Calcium Dynamics in Hippocampal Neurons (Korolev et al., 2025)

A 2025 study published in the Bulletin of Experimental Biology and Medicine examined the effect of Semax on intracellular calcium using fluorescent imaging in two rodent neuronal preparations: rat hippocampal CA1 slices and cerebellar granule cell cultures. Semax at 1 µM was reported to significantly increase the frequency of spontaneous calcium oscillations in CA1 pyramidal layer cells. No significant effect was observed on proton-stimulated calcium entry through acid-sensing ion channels (ASICs) in cerebellar granule cells. The authors concluded that ASIC inhibition in cerebellar neurons was unlikely to be the primary mechanism of Semax's reported neuroprotective activity, pointing toward hippocampal calcium signaling as a distinct research avenue [9].

N-Terminal Modification and Activity in Rat Learning Models (Levitskaya et al., 2005)

Levitskaya and colleagues (2005) systematically characterized the influence of N-terminal modifications on nootropic-like activity of Semax analogs in rat learning paradigms (food-reinforced and pain-reinforced maze tasks), publishing in Biology Bulletin [10].

Acetylation of the methionine alpha-amino group was among the modifications that retained the observed nootropic-like activity in the tested animal models, while glycine, threonine, or alanine substitutions abolished activity. The authors concluded that the first amino acid residue exerts a dominant structural role in the pharmacological profile of the heptapeptide. These findings directly informed the design rationale for N-Acetyl Semax Amidate by confirming that N-terminal acyl modification is pharmacologically tolerated in this peptide class [10].

Areas of Ongoing Investigation

Several research questions remain open for the Semax peptide family and N-Acetyl Semax Amidate specifically, representing active rather than closed frontiers:

Compound-specific characterization: The fully amidated form has not yet been examined as a primary subject in receptor binding or in vivo pharmacology studies separate from Semax. Head-to-head comparison between Semax, N-acetyl Semax, and N-Acetyl Semax Amidate in matched experimental systems would resolve how each terminal modification contributes to the observed pharmacological profile.

Receptor subtype identification: Published binding studies have not definitively assigned Semax-family pharmacology to a specific melanocortin receptor subtype (MC1R–MC5R). Subtype-selective antagonist experiments in the context of Semax's neurotrophin effects represent a tractable next step for the field.

Amide-modification effect on neurotrophin responses: Whether C-terminal amidation of N-acetyl Semax alters the BDNF or NGF gene expression profiles observed with Semax in matched animal models is a question that the existing methodology is well-positioned to address.

Stability pharmacokinetics: Formal pharmacokinetic studies characterizing plasma half-life, brain tissue penetration, and metabolite profiles specific to the fully amidated analog have not been published and would complement the existing degradation data on unmodified Semax [11]. A parallel research corpus for the anxiolytic-oriented neuropeptide Selank and its analogs — including published research on N-Acetyl Selank Amidate — provides a point of comparison for the structural pharmacology methodology used to characterize terminal-modified neuropeptides within the same Russian research tradition. Research-grade N-Acetyl Semax Amidate from SpartaLabs is supplied with batch-specific certificates of analysis documenting HPLC purity and mass spectrometry identity verification.

References

1. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, et al. Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97(Suppl 1):82–86. DOI: 10.1111/j.1471-4159.2006.03658.x

2. Shadrina MI, Kolomin TA, Agapova TY, Dolotov OV, Grivennikov IA, Slominsky PA, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010;41(1):30–35. PMID: 19662538. DOI: 10.1007/s12031-009-9270-z

3. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2006;31(3):285–292. PMID: 16362768. DOI: 10.1007/s11064-005-8826-8

4. Grivennikov IA, Dolotov OV, Zolotarev YA, Andreeva LA, Myasoedov NF, Leacher L, et al. Effects of behaviorally active ACTH(4-10) analogue — Semax on rat basal forebrain cholinergic neurons. Restor Neurol Neurosci. 2008;26(1):35–43. PMID: 18431004

5. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71–79. PMID: 19633950. DOI: 10.1007/s10571-009-9432-0

6. Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, et al. The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. PMID: 24661604. DOI: 10.1186/1471-2164-15-228

7. Sudarkina OY, Filippenkov IB, Stavchansky VV, Denisova AE, Gubsky LV, Limborska SA, et al. Brain protein expression profile confirms the protective effect of the ACTH(4–7)PGP peptide (Semax) in a rat model of cerebral ischemia–reperfusion. Int J Mol Sci. 2021;22(12):6179. PMID: 34201112. DOI: 10.3390/ijms22126179

8. Magrì A, Munzone A, Peana M, Medici S, Zoroddu MA, Hansson Ö, et al. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. J Inorg Biochem. 2016;164:59–69. PMID: 27586814. DOI: 10.1016/j.jinorgbio.2016.08.013

9. Korolev DO, Zolotarev YA, Grivennikov IA. The effect of peptide Semax, an ACTH(4-10) analogue, on intracellular calcium dynamics in rat brain neurons. Bull Exp Biol Med. 2025. DOI: 10.1007/s10517-025-06501-z

10. Levitskaya NG, Sebentsova EA, Andreeva LA, Alfeeva LY, Kamenskiy AA, Myasoedov NF. Effect of modification of the N-terminal region of Semax on the expression of nootropic effect of Semax analogs. Biol Bull. 2005;32(4):381–386. DOI: 10.1007/s10525-005-0116-0

11. Shevchenko KV, Nagaev IY, Alfeeva LY, Andreeva LA, Kamenskii AA, Levitskaia NG, et al. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Russ J Bioorg Chem. 2006;32(1):57–62. DOI: 10.1134/S1068162006010055